Toggle light / dark theme

April 2020


The COVID-19 pandemic caused by SARS-CoV-2 has brought about an unprecedented crisis, taking a heavy toll on human health, lives as well as the global economy. There are no SARS-CoV-2-specific treatments or vaccines available due to the novelty of this virus. Hence, rapid development of effective vaccines against SARS-CoV-2 is urgently needed. Here we developed a pilot-scale production of a purified inactivated SARS-CoV-2 virus vaccine candidate (PiCoVacc), which induced SARS-CoV-2-specific neutralizing antibodies in mice, rats and non-human primates. These antibodies potently neutralized 10 representative SARS-CoV-2 strains, indicative of a possible broader neutralizing ability against SARS-CoV-2 strains circulating worldwide. Immunization with two different doses (3μg or 6 μg per dose) provided partial or complete protection in macaques against SARS-CoV-2 challenge, respectively, without any antibody-dependent enhancement of infection. Systematic evaluation of PiCoVacc via monitoring clinical signs, hematological and biochemical index, and histophathological analysis in macaques suggests that it is safe. These data support the rapid clinical development of SARS-CoV-2 vaccines for humans.

One Sentence Summary A purified inactivated SARS-CoV-2 virus vaccine candidate (PiCoVacc) confers complete protection in non-human primates against SARS-CoV-2 strains circulating worldwide by eliciting potent humoral responses devoid of immunopathology.

The authors have declared no competing interest.

Human evolutionary history is rich with the interbreeding of divergent populations. Most humans outside of Africa trace about 2% of their genomes to admixture from Neanderthals, which occurred 50–60 thousand years ago1. Here we examine the effect of this event using 14.4 million putative archaic chromosome fragments that were detected in fully phased whole-genome sequences from 27,566 Icelanders, corresponding to a range of 56,388–112,709 unique archaic fragments that cover 38.0–48.2% of the callable genome. On the basis of the similarity with known archaic genomes, we assign 84.5% of fragments to an Altai or Vindija Neanderthal origin and 3.3% to Denisovan origin; 12.2% of fragments are of unknown origin. We find that Icelanders have more Denisovan-like fragments than expected through incomplete lineage sorting. This is best explained by Denisovan gene flow, either into ancestors of the introgressing Neanderthals or directly into humans. A within-individual, paired comparison of archaic fragments with syntenic non-archaic fragments revealed that, although the overall rate of mutation was similar in humans and Neanderthals during the 500 thousand years that their lineages were separate, there were differences in the relative frequencies of mutation types—perhaps due to different generation intervals for males and females. Finally, we assessed 271 phenotypes, report 5 associations driven by variants in archaic fragments and show that the majority of previously reported associations are better explained by non-archaic variants.

The Pentagon’s cutting edge science department is working to create a therapeutic “shield” that could be mass produced to provide temporary protection for people from diseases like the coronavirus, boosting their immunity until an actual vaccine is developed. The result could also help slow the viruses’ advance, buying time for hard-pressed hospitals and clinics worldwide.

The Defense Advanced Research Projects Agency, or DARPA, has funded efforts to create such therapies from studying COVID-19 samples from individuals who have already recovered from the virus. Scientists working with the organization’s Pandemic Prevention Platform (PPP) are sequencing the B cells of one individual who recovered from COVID-19. B cells create antibodies, proteins created by the human immune system to fight a particular invading microorganism.

A new technology aims to make tumors their own worst enemy in the fight against cancer — and Stanford Medicine will be the first in the world to incorporate the treatment into the clinic.

The first generation of a machine using this technology — the X1, from the company RefleXion Medical — harnesses positron emission tomography to deliver radiation that tracks a tumor in real time. This PET feedback allows the system to send beams of radiation to destroy cancerous cells with heightened precision.

Researchers hope that this “biology-guided radiotherapy” will increase accuracy, safety and efficacy of cancer radiation treatment. Stanford physicians plan to test the X1 later this year through clinical trials at Stanford Hospital. Their first step will be to obtain approval by the Food and Drug Administration.

On March 16, Moderna and the National Institute of Allergy & Infectious Diseases (NIAID) began dosing patients with mRNA-1273, its vaccine candidate against COVID-19. The second round of dosing in healthy Seattle volunteers has now begun.

Without placing too much significance on this, it is a good sign, suggesting that the trial is progressing well and there are no obvious bad side effects from the first round.

Lisa Jackson, senior investigator, Kaiser Permanente Washington Health Research Institute, who is heading the study, told USA Today that the physicians at Kaiser Permanente’s Vaccine Treatment and Evaluation Unit in Seattle don’t have results from the first round. This suggests that the study data is blinded, meaning it will not be released until a specific point in the trial.

Researchers have developed a way to modify an existing cancer drug with toxic side effects into something that is less toxic to blood platelets and more effective at removing harmful and inflammatory senescent cells, one of the reasons we age, from mice.

What are senescent cells?

As you age, increasing numbers of your cells enter into a state known as senescence. Senescent cells do not divide or support the tissues of which they are part; instead, they emit a range of potentially harmful chemical signals that encourage nearby healthy cells to enter the same senescent state. Their presence causes many problems: they reduce tissue repair, increase chronic inflammation, and can even eventually raise the risk of cancer and other age-related diseases.